Offering AmpliSeq V2 Panel through CLIA Lab, Mayo Pushes More Routine Cancer Sequencing | GenomeWeb

NEW YORK (GenomeWeb) — The Mayo Clinic last week announced that it will offer a test based on Ion Torrent's AmpliSeq V2 cancer hotspot panel through its CLIA-certified Next-Generation Sequencing Lab, a move that the clinic expects will routinize use of the 50-gene panel in the care of patients with a variety of solid tumors.

The AmpliSeq panel test, called CANCP, joins just one other NGS test, a 17-gene hereditary colon cancer assay, offered through the CLIA lab to Mayo physicians and to providers worldwide through the clinic's Mayo Medical Laboratories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.